Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + hormone therapy + hypofractionated radiotherapy in elderly HR+ / HER2- breast cancer
2022-501527-24-00Phase 2Completed
- Sponsor
- Centre Antoine Lacassagne
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Centre Antoine Lacassagne. Primary endpoints: Dose-limiting toxicity frequency during radiotherapy and 3-month follow-up (Phase I) and Non-progression rate at 24 months after concomitant phase (Phase II). Started Apr 2023; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-501527-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501527-24-00.